SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
基本信息
- 批准号:2213034
- 负责人:
- 金额:$ 100万
- 依托单位:
- 依托单位国家:美国
- 项目类别:Cooperative Agreement
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-15 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to improve the clinical outcomes and quality of life for patients suffering from complicated urinary tract infections (cUTI). Today, cUTIs account for 400,000 hospitalizations annually in the United States. Unfortunately, multidrug resistant pathogens are a common cause of cUTI. Many are resistant to the first-line antibiotic (Ceftriaxone), which is used as the empiric treatment of this condition. However, the high incidence of multidrug resistant pathogens causing cUTI delays the time until patients receive more appropriate treatment. Delayed time to appropriate therapy in cUTI has been attributed to extended hospital stays and an increased risk of morbidity and mortality. The current standard test for diagnosing a drug-resistant cUTI takes 2-3 days from obtaining a patient sample. Therefore, diagnostic tests that can rapidly inform the initial treatment of UTIs are urgently needed to improve patient care.This Small Business Innovation Research (SBIR) Phase II project aims to develop a rapid urinary diagnostic test that will enable the detection of ceftriaxone-resistant uropathogens. Early detection of resistance to first-line therapies would enable antibiotic prescribing to be informed, reducing the risk of disease progression in patients. In the case of UTIs, disease progression can lead to severely invasive infections, predominately sepsis. Therefore, diagnostics that can detect resistance to first-line antibiotics enable early treatment interventions, reducing the time to appropriate treatment and reducing the risk of disease progression. Decreased treatment time also lowers the healthcare costs associated with drug-resistant cUTI, as disease progression is associated with increased lengths of hospital stays compared to susceptible infections. The completion of the Phase II project will yield the development of a prototype test that can provide actionable information regarding ceftriaxone susceptibility in less than 5 minutes. This project’s success will provide clinicians with a diagnostic solution for cUTIs that can be acted on immediately to improve patient outcomes and aid antibiotic stewardship by preventing the unnecessary use of inappropriate antibiotics.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
小型企业创新研究(SBIR)第二阶段项目的更广泛影响/商业潜力是改善复杂性尿路感染(CUTI)患者的临床结果和生活质量。今天,在美国,每年有40万人因皮肤病住院。不幸的是,多药耐药病原体是cUTI的常见原因。许多人对一线抗生素(头孢曲松)具有耐药性,头孢曲松是这种疾病的经验性治疗方法。然而,引起cUTI的多重耐药病原体的高发病率推迟了时间,直到患者接受更适当的治疗。CUTI的适当治疗时间延迟是由于住院时间延长以及发病率和死亡率增加。目前诊断耐药cUTI的标准测试需要2-3天才能获得患者样本。因此,迫切需要能够为尿路感染的初始治疗提供快速信息的诊断测试,以改善患者的护理。这项小型企业创新研究(SBIR)第二阶段项目旨在开发一种快速尿路诊断测试,使对头孢曲松耐药的尿路病原体能够被检测出来。及早发现对一线治疗的耐药性将使抗生素处方能够得到通知,从而降低患者疾病进展的风险。在尿路感染的情况下,疾病的进展可导致严重的侵袭性感染,主要是败血症。因此,能够检测出对一线抗生素的耐药性的诊断方法使早期治疗干预成为可能,从而缩短适当治疗的时间并降低疾病进展的风险。治疗时间的减少也降低了与耐药cUTI相关的医疗成本,因为与易感感染相比,疾病进展与住院时间的延长有关。第二阶段项目的完成将产生一种原型测试的开发,该测试可以在不到5分钟的时间内提供有关头孢曲松敏感性的可行信息。该项目的成功将为临床医生提供一种皮肤炎症性疾病的诊断解决方案,该解决方案可以立即采取行动,通过防止不必要的不适当抗生素的使用来改善患者的预后并帮助抗生素管理。该奖项反映了NSF的法定使命,并通过使用基金会的智力价值和更广泛的影响审查标准进行评估,被认为值得支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Angel Resendez其他文献
Diisobutylaluminum borohydride: An efficient reagent for the reduction of tertiary amides to the corresponding amines under ambient conditions
二异丁基硼氢化铝:在环境条件下将叔酰胺还原成相应胺的有效试剂
- DOI:
10.1016/j.tetlet.2017.09.030 - 发表时间:
2017 - 期刊:
- 影响因子:1.8
- 作者:
Rachel Snelling;Gabriella Amberchan;Angel Resendez;Chris L. Murphy;Lauren Porter;B. Singaram - 通讯作者:
B. Singaram
Beyond Glucose Recognition: Development of a Multiwell Assay for the Recognition of Sugars and Sugar Derivatives as GI Permeability Markers
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:2.4
- 作者:
Angel Resendez - 通讯作者:
Angel Resendez
A smart probe for detection of sugar markers for applications in gastrointestinal barrier dysfunction
一种用于检测糖标记物的智能探针,应用于胃肠屏障功能障碍
- DOI:
10.1016/j.bios.2024.117040 - 发表时间:
2025-03-15 - 期刊:
- 影响因子:10.500
- 作者:
Fatih Inci;Angel Resendez;Merve Goksin Karaaslan;Mallesh Pandrala;Amideddin Mataji Kojouri;Rajib Ahmed;Mehmet Giray Ogut;Bakthan Singaram;Sanjay V. Malhotra;Utkan Demirci - 通讯作者:
Utkan Demirci
Angel Resendez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Angel Resendez', 18)}}的其他基金
SBIR Phase I: Development of point-of-care diagnostics to direct the appropriate use of antibiotics for the treatment of high-risk urinary tract infections
SBIR 第一阶段:开发即时诊断,指导正确使用抗生素治疗高危尿路感染
- 批准号:
2014629 - 财政年份:2020
- 资助金额:
$ 100万 - 项目类别:
Standard Grant
相似国自然基金
Baryogenesis, Dark Matter and Nanohertz Gravitational Waves from a Dark
Supercooled Phase Transition
- 批准号:24ZR1429700
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
ATLAS实验探测器Phase 2升级
- 批准号:11961141014
- 批准年份:2019
- 资助金额:3350 万元
- 项目类别:国际(地区)合作与交流项目
地幔含水相Phase E的温度压力稳定区域与晶体结构研究
- 批准号:41802035
- 批准年份:2018
- 资助金额:12.0 万元
- 项目类别:青年科学基金项目
基于数字增强干涉的Phase-OTDR高灵敏度定量测量技术研究
- 批准号:61675216
- 批准年份:2016
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Phase-type分布的多状态系统可靠性模型研究
- 批准号:71501183
- 批准年份:2015
- 资助金额:17.4 万元
- 项目类别:青年科学基金项目
纳米(I-Phase+α-Mg)准共晶的临界半固态形成条件及生长机制
- 批准号:51201142
- 批准年份:2012
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
连续Phase-Type分布数据拟合方法及其应用研究
- 批准号:11101428
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
D-Phase准晶体的电子行为各向异性的研究
- 批准号:19374069
- 批准年份:1993
- 资助金额:6.4 万元
- 项目类别:面上项目
相似海外基金
SBIR Phase II: Innovative Two-Phase Cooling with Micro Closed Loop Pulsating Heat Pipes for High Power Density Electronics
SBIR 第二阶段:用于高功率密度电子产品的创新两相冷却微闭环脉动热管
- 批准号:
2321862 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Innovative Glass Inspection for Advanced Semiconductor Packaging
SBIR 第二阶段:先进半导体封装的创新玻璃检测
- 批准号:
2335175 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Intelligent Language Learning Environment
SBIR第二阶段:智能语言学习环境
- 批准号:
2335265 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
SBIR Phase II: FlashPCB Service Commercialization and AI Component Package Identification
SBIR第二阶段:FlashPCB服务商业化和AI组件封装识别
- 批准号:
2335464 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Thermally-optimized power amplifiers for next-generation telecommunication and radar
SBIR 第二阶段:用于下一代电信和雷达的热优化功率放大器
- 批准号:
2335504 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Sodium-Based Solid-State Batteries for Stationary Energy Storage
SBIR第二阶段:用于固定储能的钠基固态电池
- 批准号:
2331724 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
SBIR Phase II: A mesh-free, sling-free, minimally invasive treatment for stress urinary incontinence in women
SBIR II 期:无网、无吊带的微创治疗女性压力性尿失禁
- 批准号:
2233106 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Zero Trust Solution for Precision Medicine and Precision Health Data Exchanges
SBIR 第二阶段:精准医疗和精准健康数据交换的零信任解决方案
- 批准号:
2226026 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
SBIR Phase II: High-Performance Batteries to Decarbonize Heavy Duty Construction Equipment
SBIR 第二阶段:高性能电池使重型建筑设备脱碳
- 批准号:
2335320 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement
SBIR Phase II: Technology for Stimulating the Herd Instinct of Livestock to Reduce Environmental Impact
SBIR第二阶段:刺激牲畜的群体本能以减少环境影响的技术
- 批准号:
2335554 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Cooperative Agreement